Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMDWJCT)

Drug Name
CSL346 Drug Info
Indication
Disease Entry ICD 11 Status REF
Diabetic kidney disease GB61.Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMDWJCT

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial growth factor B (VEGFB) TTPJQHE VEGFB_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Vascular endothelial growth factor B (VEGFB) DTT VEGFB 6.333 6.18 5.812 5.739
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diabetic kidney disease
ICD Disease Classification GB61.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor B (VEGFB) DTT VEGFB 2.75E-01 -0.2 -0.45
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04419467) A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease. U.S.National Institutes of Health.